<!DOCTYPE html>

<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/ -->
<!--[if lt IE 7]> <html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en"> <![endif]-->
<!--[if IE 7]>    <html class="no-js lt-ie9 lt-ie8" lang="en"> <![endif]-->
<!--[if IE 8]>    <html class="no-js lt-ie9" lang="en"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js" lang="en"> <!--<![endif]-->
<head>
	<meta charset="utf-8" />

	<!-- Set the viewport width to device width for mobile -->
	<meta name="viewport" content="width=device-width" />

	<title>Practice Network : News Item</title>

	<!-- Included CSS Files -->
<!-- FontDeck
<link rel="stylesheet" href="http://f.fontdeck.com/s/css/l4MsFun30OJhB9DTDGcb8JQSAOQ/practicenetwork-foundation/22889.css" type="text/css" /> 
-->

	<link rel="stylesheet" href="assets/css/app.css">
	<link rel="stylesheet" href="assets/css/font-awesome.css">
	<link rel="stylesheet" href="assets/css/fc-webicons.css">
	<link rel="stylesheet" href="assets/css/foundation-icons-general.css">

	<script src="assets/js/foundation/modernizr.foundation.js"></script>

	<!-- IE Fix for HTML5 Tags -->
	<!--[if lt IE 9]>
		<script src="http://html5shiv.googlecode.com/svn/trunk/html5.js"></script>
	<![endif]-->

</head>
	<body id="page" class="update off-canvas slide-nav news-item logged-out">
  <div class="widget ad">
    <div id="leaderboard" class="Breast ad-container">
      <div class="ad-title"><span class="ad-title-text">advertisement</span></div><!--/.ad-title-->
      <div id="leaderboardcontent" class="ad-content">
			</div><!--.ad-content-->
		</div><!--/#leaderboard.ad-container-->
  </div><!--/.widget.ad-->
	<div class="page-header">
	</div><!--/.page-header-->
	<div class="page-content">
	<section role="main">

<div class="single-item-container">
	<article class="type-blog">
	<header class="item-header">
		<hgroup>
		<!-- <div class="meta pub-meta">
			<time class="meta pub-pubdate" datetime="2012-03-05">March 5th, 2012</time>
			<span class="meta pub-attribution">Howard Scher, MD</span>
		</div> -->
			<h1 class="item-title">Second-Line FOLFIRI/Aflibercept Ups Survival in Metastatic Colorectal Cancer</h1>
			<p class="item-citation">{{source.citation}}</p>
		</hgroup>
			<!-- <p class="source"> --><!-- {{source}} --><!-- J Clin Oncol. 2012 Aug 27;[Epub Ahead of Print], HSL Jim, KM Phillips, S Chait</p>--><!--/.source-->
			<!-- <h2 class="item-subtitle">Article Subtitle - Optional</h2> -->
		<!-- <div class="item-description">
			<p>In this commentary, Dr. Scher discusses his research on a novel androgen receptor signaling inhibitor, MDV3100, which was shown to improve survival in a post-chemotherapy population of men with progressive castration-resistant prostate cancer (CRPC).</p>
		</div> --><!--/.description-->
			<!-- <div class="meta taxonomy-meta">
			<p>Find more items about these topics:</p>
			<ul class="tag-list">
				<li>
					<i class="icon-tags"></i><a class="label label-tag" href="#">Prostate</a>
				</li> -->
			<!-- </ul> --><!--/.tag-list-->
		<!-- </div> --><!--/.taxonomy-meta-->
	</header>
	<div class="item-content">
		<div class="item-content-section">
			<section class="commentary">
				<div class="commentary-container">
						<p>Metastatic colorectal cancer is generally treated initially with a regimen of fluorouracil and leucovorin plus either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI). Patients cross over to the alternate regimen for second-line therapy. The antiangiogenic agent bevacizumab has been shown to increase survival in patients with metastatic colorectal cancer in the first-line setting when added to FOLFIRI and in the second-line setting when added to FOLFOX, but no biologic agent has been shown to improve survival in the second-line setting when added to FOLFIRI.</p><p>Aflibercept is a recombinant fusion protein that targets three factors that contribute to tumor angiogenesis: vascular endothelial growth factor A (VEGFA), VEGFB, and placental growth factor (PlGF). In a multinational phase III study sponsored by Sanofi, Van Cutsem et al added aflibercept to FOLFIRI as second-line therapy for metastatic colorectal cancer previously treated with oxaliplatin. Prior bevacizumab was allowed, but not prior irinotecan.</p><p>Between 2007 and 2010, a total of 1226 patients were randomized to receive aflibercept 4 mg/kg (n = 612) or placebo (n = 614) on day 1 every 2 weeks, followed by the FOLFIRI regimen (irinotecan 180 mg/m2, leucovorin 400 mg/m2, and fluorouracil 400 mg/m2 bolus and then 2400 mg/m2 by continuous infusion). Crossover to aflibercept after progression on placebo was not permitted.</p><p>At the February 2011 cutoff date for analysis of overall survival (OS), the primary endpoint, median follow-up was 22.28 months. The patients receiving aflibercept/FOLFIRI had a median survival of 13.50 months compared with 12.06 months for the placebo/FOLFIRI control patients (hazard ratio [HR], 0.817; P = .0032). At 2 years, survival rates were 28.0% and 18.7%, respectively. The treatment effect favoring aflibercept held in analyses of prespecified subgroups based on prior bevacizumab use and various patient characteristics at baseline.</p><p>Progression-free survival (PFS) increased from 4.7 months for controls to 6.9 months with use of aflibercept (HR, 0.758; P &lt; .0001). Subgroup analyses showed a consistent trend in PFS in favor of aflibercept. The response rate in patients with measurable disease was significantly higher with aflibercept vs placebo (19.8% vs 11.1%; P &lt; .001).</p><p>Grade 3 and 4 adverse events were more common with aflibercept than placebo (83.5% vs 62.5%, respectively). Toxicities related to anti-VEGF treatment were consistent with those reported in previous studies. Interestingly, some common adverse events related to treatment with FOLFIRI were more frequent in the aflibercept arm. These included grade 3 and 4 diarrhea, asthenia, stomatitis, infections, and palmar&#8211;plantar erythrodysesthesia, as well as grade 3 and 4 neutropenia, thrombocytopenia, and neutropenic complications.</p><p>The addition of aflibercept to FOLFIRI led to a relative reduction in the risk of death of 18.3%, compared with placebo/FOLFIRI. The early and continued divergence of the survival curves further supports the clinical value of the aflibercept results. Survival rates for aflibercept vs placebo were 38.5% vs 30.9% at 18 months, 28.0% vs 18.7% at 24 months, and 22.3% vs 12.0% at 30 months.</p><p>The authors concluded that aflibercept plus FOLFIRI may be a new therapeutic option for the treatment of metastatic colorectal cancer patients whose disease has progressed while on or after completion of an oxaliplatin-based regimen.</p>
				</div><!--/.commentary-container-->
			</section><!-- /.commentary-->
		</div><!-- ./item-content-section -->

			<hr />
	</div>
<footer class="copyright item-footer">
<img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"/>
<p>Copyright &copy; 2012 International Medical News Group</p>
</footer>
</div><!--/.item-container-->
				<div class="recommended">
				<div class="recent">
				</div><!--/.recent-->
				<div class="ad">
					<img src="http://placehold.it/300x250" align="ad" title="ad" />
				</div>
				</div><!--/.recommended-->

	</section><!--/[role="main"]-->
	<section id="sidebar" role="complementary">
		<div class="dashboard">
			<div class="panel cta register">
				<p><!-- Meet Our Experts --> Become a member to customize this page.<p>
				<a class="button" href="#action-register">Register for free</a>
			</div><!--/.panel.cta.register-->
			<div class="component user-console">
			</div><!--/.component.user-console-->

			<div class="component user-specialties">
			</div><!--/.component.user-specialties-->
			<div class="component topic-spotlight">
			</div><!--/.component.topic-spotlight-->
			<div class="panel">
				<img src="http://placehold.it/200x200" /><p><!-- Meet Our Experts --> Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.<p>
			</div>
		</div><!--/.sidebar-->
	</section><!--/.[role="complimentary"]-->
</div><!--/.page-content-->
	<footer class="page-footer">
	</footer><!-- /.page-footer -->

	<!-- Included JS Files (Uncompressed) -->
  <script src="assets/js/foundation/jquery.js"></script>
  
	<script src="assets/js/foundation/jquery.foundation.accordion.js"></script>
	<script src="assets/js/foundation/jquery.foundation.alerts.js"></script>	
	<script src="assets/js/foundation/jquery.foundation.buttons.js"></script>
	<script src="assets/js/foundation/jquery.foundation.forms.js"></script>
	<script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js"></script>
	<script src="assets/js/foundation/jquery.foundation.navigation.js"></script>
	<script src="assets/js/foundation/jquery.foundation.orbit.js"></script>
	<script src="assets/js/foundation/jquery.foundation.reveal.js"></script>
	<script src="assets/js/foundation/jquery.foundation.tabs.js"></script>
	<script src="assets/js/foundation/jquery.foundation.tooltips.js"></script>
	<script src="assets/js/foundation/jquery.placeholder.js"></script>


	<script src="assets/js/foundation/app.js"></script>
	<script src="assets/js/foundation/jquery.offcanvas.js"></script>

	<script src="assets/js/mustache.js"></script>

	<!-- Mustache - homepage feed template -->
	<script>
	<!-- Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
		$.get('assets/mustache/feed-item.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.stream-container').html(html);
		});

	});

	<!-- Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
		$.get('assets/mustache/recent.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.recent').html(html);
		});

	});

	<!-- Mustache - homepage user-console template -->
	$.getJSON('content/json/user-console.json', function(data) {
		$.get('assets/mustache/user-console.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.user-console').html(html);
		});
	});

		<!-- Mustache - homepage user-specialties template -->
	$.getJSON('content/json/user-specialties.json', function(data) {
		$.get('assets/mustache/user-specialties.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.user-specialties').html(html);
		});
	});

	<!-- Mustache - homepage topic-spotlight template -->
	$.getJSON('content/json/topic-spotlight.json', function(data) {
		$.get('assets/mustache/topic-spotlight.mustache', function(template) {
			//alert('Load was performed.');
	    var html = Mustache.to_html(template, data);
	    $('.topic-spotlight').html(html);
		});
	});	
	</script>

</body>
</html>